The Primary
Care Companionfor CNS Disorders

Schizophrenia/Schizoaffective Disorders

Letter to the Editor June 1, 2004

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis

Thomas J. Kim, MD, MPH ; H. W. LeBourgeois III, MD

Prim Care Companion J Clin Psychiatry 2004;6(3):136-137

Article Abstract

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis.

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 27 • 2025 • Number 1

Read the Current Issue

Original Research

Suicide-Specific Cognitions in US Military Veterans

Original Research

Irritability and Geriatric Depression

Rounds in the General Hospital

Prolonged Grief: Etiology and Management

Original Research

Impact of Lemborexant on Daytime Functioning

Rounds in the General Hospital

Management of Insomnia in the General Hospital

Case Report

Hypnotic Suggestion in Ketamine-Assisted Psychotherapy

View current Issue

Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...

Xintong Mu , Hiroyoshi Takeuchi

Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.

Rif S. El-Mallakh

Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.

Florian Naudet , André Gillibert , Barbara Mintzes , et al

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis

Read the Current Issue

Suicide-Specific Cognitions in US Military Veterans

Irritability and Geriatric Depression

Prolonged Grief: Etiology and Management

Impact of Lemborexant on Daytime Functioning

Management of Insomnia in the General Hospital

Hypnotic Suggestion in Ketamine-Assisted Psychotherapy

ELSEWHERE:

FOLLOW US:

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis

Read the Current Issue

Suicide-Specific Cognitions in US Military Veterans

Irritability and Geriatric Depression

Prolonged Grief: Etiology and Management

Impact of Lemborexant on Daytime Functioning

Management of Insomnia in the General Hospital

Hypnotic Suggestion in Ketamine-Assisted Psychotherapy

Related Articles

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

Asenapine, Aggression, and Affinity

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles